Cologuard is an at-home colon cancer screening kit that detects changes in genetic material indicating potential cancer or polyps. Medicare covers one kit per year under Original Medicare (Parts A and ...

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

Let’s start with the cheapest, the yearly FIT, or fecal immunochemical test, which looks for fecal blood that might be caused ...

The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the firm's quarterly execution and forecast don't reflect its full potential.

Exact Sciences shares plunged Wednesday after the maker of Cologuard reported widening losses and cut its outlook.

Which mold test kit is best? Mold growth in your home is more than just unpleasant. Foul odors, property damage and health ...

Researchers at University of California San Francisco (UCSF) have developed a single genomic test that can quickly detect ...

The Cologuard Plus test is now approved for adults ages 45 and older who are average risk for colorectal cancer (CRC).1 MADISON, Wis., September 16, 2024--Exact Sciences Corp. (NASDAQ: EXAS), a ...

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million. The average estimate of six ...